Angiotensin II (ANG II) is known to be a potent growth promoting factor for vascular smooth muscle cells and fibroblasts but little is known about its influence on growth in endothelial cells. We studied the effects of ANG II on endothelial growth and the role of the angiotensin receptor subtypes involved. Proliferation of rat coronary endothelial cells (CEC) and rat vascular smooth muscle cells (VSMC) was determined by [3H]thymidine incorporation, the MTT-test and by directly counting cells in a coulter counter. Angiotensin AT1- and AT2-receptors were demonstrated by binding studies and by the presence of their respective mRNA through reverse transcription polymerase chain reaction (RT-PCR). In contrast to VSMC, which in culture only express the AT1-receptor, CEC express both, AT1- and AT2-receptors simultaneously up to the third passage. Whereas ANG II stimulated growth of quiescent VSMC, an effect abolished by pretreatment with the AT1-receptor antagonist, losartan, ANG II did not induce proliferation in quiescent CEC. However, after pretreatment of quiescent endothelial cells (< passage 4) with the AT2-receptor antagonist, PD 123177, ANG II induced proliferation. This effect was reversed by additional pretreatment with losartan. ANG II significantly inhibited the proliferation of bFGF-stimulated CEC in a dose-dependent manner by maximally 50%. This effect was prevented by PD 123177 while losartan was ineffective. The AT2-receptor agonist, CGP 42112, mimicked the antiproliferative actions of ANG II, confirming the specificity of the effect. Our results show that the growth modulating actions of ANG II depend on the type of angiotensin receptor present on a given cell. In coronary endothelial cells, the antiproliferative actions of the AT2-receptor offset the growth promoting effects mediated by the AT1-receptor.
M Stoll, U M Steckelings, M Paul, S P Bottari, R Metzger, T Unger
Title and authors | Publication | Year |
---|---|---|
Local Fetal Lung Renin-Angiotensin System as a Target to Treat Congenital Diaphragmatic Hernia
C Nogueira-Silva, E Carvalho-Dias, P Piairo, S Nunes, MJ Baptista, RS Moura, J Correia-Pinto |
Molecular Medicine | 2012 |
The effects of angiotensin peptides and angiotensin receptor antagonists on the cell growth and angiogenic activity of GH3 lactosomatotroph cells in vitro
D Ptasinska-Wnuk, SA Mucha, H Lawnicka, J Fryczak, J Kunert-Radek, M Pawlikowski, H Stepien |
Endocrine | 2012 |
Impact of the AT2 Receptor Agonist C21 on Blood Pressure and Beyond
S Foulquier, UM Steckelings, T Unger |
Current Hypertension Reports | 2012 |
Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium
J Carbajo-Lozoya, S Lutz, Y Feng, J Kroll, HP Hammes, T Wieland |
Cellular Signalling | 2012 |
Angiotensin II type 2 receptor agonists: where should they be applied?
K Verdonk, AH Danser, JH van Esch |
Expert Opinion on Investigational Drugs | 2012 |
Muscle
ML Martin, SL Belmonte, R Ram, FA Kamal, BC Blaxall |
Muscle | 2012 |
Update on the Angiotensin AT2 Receptor
CA McCarthy, RE Widdop, KM Denton, ES Jones |
Current Hypertension Reports | 2012 |
AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression
P Namsolleck, F Boato, K Schwengel, L Paulis, K Matho, N Geurts, C Thöne-Reineke, K Lucht, K Seidel, A Hallberg, B Dahlöf, T Unger, S Hendrix, UM Steckelings |
Neurobiology of Disease | 2012 |
Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth
A Kawabata, A Baoum, N Ohta, S Jacquez, GM Seo, C Berkland, M Tamura |
Cancer research | 2012 |
Statins and selective inhibition of Rho kinase protect small conductance calcium-activated potassium channel function (K(Ca)2.3) in cerebral arteries
AJ McNeish, F Jimenez-Altayo, GS Cottrell, CJ Garland |
PloS one | 2012 |
A Non-peptide Angiotensin II Type 2 Receptor Agonist Does Not Attenuate Post-Myocardial Infarction Left Ventricular Remodeling in Mice
AB Jehle, Y Xu, JM DiMaria, BA French, FH Epstein, SS Berr, RJ Roy, BA Kemp, RM Carey, CM Kramer |
Journal of Cardiovascular Pharmacology | 2012 |
A new transgenic rat model overexpressing the angiotensin II type 2 receptor provides evidence for inhibition of cell proliferation in the outer adrenal cortex
B Peters, D Podlich, M Ritter, A Müller, H Wanka, C Maser-Gluth, C Seitz, L Boni, E Maier, N Gretz, J Peters, SC Hoffmann |
American journal of physiology. Endocrinology and metabolism | 2012 |
Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation
J Kim, HJ Jang, LA Martinez-Lemus, JR Sowers |
American journal of physiology. Endocrinology and metabolism | 2012 |
Angiotensin II regulates activation of Bim via Rb/E2F1 during apoptosis: involvement of interaction between AMPKβ1/2 and Cdk4
YC Kim, RM Day |
American journal of physiology. Lung cellular and molecular physiology | 2012 |
The effect of losartan on angiotensin II-induced cell proliferation in a rat aorta smooth muscle cell line
N Tambelline, K Oliveira, LR Olchanheski, R Sordi, MF Otuki, GM Favero, D Fernandes |
Brazilian Archives of Biology and Technology | 2012 |